Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma
BMC Gastroenterology · 2024
DOI: 10.1186/s12876-024-03387-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Mohamed Kohla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minufiya University.
Abstract (Originalsprache)
Background
Accurate staging is necessary for predicting hepatocellular carcinoma (HCC) prognosis and guiding patient management. The Barcelona Clinic Liver Cancer (BCLC) staging system has limitations due to heterogeneity observed among patients in BCLC stages B and C. In contrast, the Hong Kong Liver Cancer (HKLC) staging system offers more aggressive treatment strategies.
Aim
To compare the prognostic performance of HKLC and BCLC staging systems in Egyptian patients with HCC.
Methods
We conducted a retrospective study at the National Liver Institute, Menoufia University, Egypt, on 1015 HCC patients. Data was collected from patients’ medical records over 10 years (from 2008 to 2018). The BCLC and HKLC stages were identified, and Kaplan-Meier survival analysis was used to compare patients’ overall survival rates within each staging system. Additionally, we evaluated the comparative prognostic performance of the two staging systems.
Results
Hepatitis C was identified as the underlying etiology in 799 patients (78.7%), hepatitis B in 12 patients (1.2%), and non-viral causes in 204 patients (20.1%). The survival analysis demonstrated significant differences across the various stages within both the BCLC and HKLC systems. The receiver operating characteristic (ROC) curves indicated a marginally superior performance of the HKLC system in predicting survival at 1, 2, and 3 years compared to the BCLC system. Furthermore, the HKLC staging provided a slightly enhanced prognostic capability, particularly for patients classified under BCLC stages B and C, suggesting a potential survival benefit.
Conclusion
HKLC classification had a slightly better prognostic performance than BCLC staging system and may offer a survival advantage for certain patients with HCC in BCLC stage B and C HCC cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt.
- Department of Diagnostic Medical Imaging and Interventional Radiology, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt.
- Department of Hepatopancreatobiliary surgery, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt.
- Department of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Shebin El-Kom, 32511, Egypt. drsallywaheed@liver.menofia.edu.eg.
Förderung
- Minufiya University
Zitieren
APA
Kohla, M., Ashour, R., Taha, H., El-Abd, O., Osman, M., Abozeid, M., & ELKhadry, S. W. (2024). Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03387-5
Vancouver
Kohla M, Ashour R, Taha H, El-Abd O, Osman M, Abozeid M, et al. Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03387-5
BibTeX
@article{Kohla2024,
author = {Kohla, Mohamed and Ashour, Reham and Taha, Hossam and El-Abd, Osama and Osman, Maher and Abozeid, Mai and ELKhadry, Sally Waheed},
title = {Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma},
journal = {BMC Gastroenterology},
year = {2024},
doi = {10.1186/s12876-024-03387-5}
}
EUVIMED